Vantia Therapeutics has reported that its novel oral small molecule drug for the treatment of dysmenorrhoea (painful menstruation) has entered phase II proof-of-concept trials. In addition, the company
Particle Sciences has revealed that Dow Corning has partnered with the company to develop technology for its product development project. The company said that it is leveraging its
Cryo-Cell International (Cryo-Cell) has reported the progress in the fight against breast cancer through research and development using stem cells from menstrual blood. The company said that it
FDA has provided a complete response letter to Genzyme regarding its supplemental New Drug Application for Clolar (clofarabine) in previously untreated older adult patients with acute myeloid leukemia
Transdel Pharmaceuticals (Transdel) has reported positive top-line clinical results for its lead pain drug, Ketotransdel, in a phase 3 trial. The study evaluated the efficacy and safety of
Helix BioPharma has provided updates on progress in its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs, following pre-investigational new drug (pre-IND) meetings with the FDA. In
Gen-Probe has signed an agreement to acquire Prodesse for approximately $60m in cash. Gen-Probe’s purchase price could increase to up to $85m if Prodesse achieves certain financial and
Novartis has completed its entire shipment of seasonal influenza vaccine to the US for the 2009/2010 season. As anticipated, the company delivered 27 million doses of Fluvirin influenza
The European Commission (EC) has approved UCB’s Cimzia, in combination with MTX, for the treatment of moderate to severe active RA in adult patients inadequately responsive to disease-modifying
Genentech, a wholly-owned member of the Roche Group, has reported results from two phase III studies of Lucentis (ranibizumab injection) in macular edema due to retinal vein occlusion
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.